Skip to main content
Glama

Ct Count By Condition

ct_count_by_condition
Read-onlyIdempotent

Count clinical trials for a condition or disease, broken down by recruitment status and by trial phase — how many are recruiting, completed, terminated, and how many are Phase 1, 2, 3 or 4. Use for landscape questions about how much trial activity a disease has and where it sits in development. Filtering by status or phase returns the filtered total without the breakdown.

Input Schema

TableJSON Schema
NameRequiredDescriptionDefault
phaseNoOptional phase filter: PHASE1, PHASE2, PHASE3, PHASE4
statusNoOptional status filter: RECRUITING, COMPLETED, etc.
conditionYesCondition or disease (e.g., "breast cancer", "diabetes", "Alzheimer")

Output Schema

TableJSON Schema
NameRequiredDescriptionDefault
conditionYesCondition queried
total_countYesTotal matching trial count
phase_filterYesApplied phase filter or 'all'
status_filterYesApplied status filter or 'all'

TDQS

A4.4/5.0
Behavior4/5

Does the description disclose side effects, auth requirements, rate limits, or destructive behavior?

Annotations already declare readOnlyHint=true, openWorldHint=true, idempotentHint=true, and destructiveHint=false, so the safety profile is clear. The description adds value by detailing the output shape (breakdown by status and phase) and the effect of filters on the output, which goes beyond what the annotations provide.

Agents need to know what a tool does to the world before calling it. Descriptions should go beyond structured annotations to explain consequences.

Conciseness5/5

Is the description appropriately sized, front-loaded, and free of redundancy?

The description is three sentences, front-loaded with the core action ('Count clinical trials...'), followed by usage context and filter behavior. No word is wasted; every sentence adds useful information.

Shorter descriptions cost fewer tokens and are easier for agents to parse. Every sentence should earn its place.

Completeness4/5

Given the tool's complexity, does the description cover enough for an agent to succeed on first attempt?

With an output schema present, the description doesn't need to detail return values. It covers purpose, usage, and filter behavior. Minor gaps: it doesn't specify how simultaneous status and phase filters interact or what happens when no trials match, but these are edge cases likely covered by the output schema.

Complex tools with many parameters or behaviors need more documentation. Simple tools need less. This dimension scales expectations accordingly.

Parameters4/5

Does the description clarify parameter syntax, constraints, interactions, or defaults beyond what the schema provides?

Schema coverage is 100%, so the baseline is 3. The description adds extra semantics by explaining that status/phase are filters that change the response to a single total without breakdown, contextualizing the condition parameter as the primary grouping entity. This enhances the schema descriptions.

Input schemas describe structure but not intent. Descriptions should explain non-obvious parameter relationships and valid value ranges.

Purpose5/5

Does the description clearly state what the tool does and how it differs from similar tools?

The description uses a specific verb ('Count'), explicitly names the resource ('clinical trials'), and specifies the breakdown by recruitment status and trial phase. This clearly distinguishes it from sibling tools like ct_search or ct_get_study, which retrieve individual trials rather than aggregate counts.

Agents choose between tools based on descriptions. A clear purpose with a specific verb and resource helps agents select the right tool.

Usage Guidelines4/5

Does the description explain when to use this tool, when not to, or what alternatives exist?

The description gives a clear use case: 'Use for landscape questions about how much trial activity a disease has and where it sits in development.' It also explains the behavior of filtering ('Filtering by status or phase returns the filtered total without the breakdown'). While it doesn't explicitly name alternative tools, the context is sufficient to guide appropriate use.

Agents often have multiple tools that could apply. Explicit usage guidance like "use X instead of Y when Z" prevents misuse.

Try in Browser

Glama MCP Gateway

Add one secure layer between your agents and this server.

TDQS

A3.9/5.0
Disambiguation3/5

Tool families overlap in purpose—ask_pipeworx/ask_pipeworx_beta/ask_pipeworx_grounded, ct_search/ct_count_by_condition/ct_competitive_landscape, and ct_sponsor_trials/ct_sponsor_pipeline/ct_sponsor_activity all present multiple plausible entry points. The very detailed, cross-referenced descriptions help, but an agent still has to read carefully to avoid misselection.

Naming Consistency4/5

Nearly all tool names follow lowercase snake_case with recognizable prefixes like ct_, polymarket_, and pipeworx_, giving the set a strong overall pattern. The main deviation is noun-phrase names such as recent_changes, entity_profile, and pipeworx_trending instead of a more uniform verb-first convention.

Tool Count2/5

44 tools is far too many for a server named Clinicaltrials: only 13 are ct_* tools, while the other 31 are broad Pipeworx utilities covering prediction markets, memory, subscriptions, npm scanning, and AI visibility. The clinical-trial module itself is well-sized, but the server bundles substantial unrelated surface area.

Completeness4/5

The clinical-trial workflow is nearly complete: search, study details, results, counts, sponsor comparison and pipeline, location lookup, update tracking, and landscape mapping are all covered. Minor conveniences like saved searches or export are missing, but agents can work around them; there are no dead ends in the registry domain.